Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Slides:

Advertisements

Similar presentations

Biologics in Asthma—The Next Step Toward Personalized Treatment

Advertisements

Pinja Ilmarinen, PhD, Leena E

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Advances in Diagnosing Peanut Allergy

Risk of an asthma exacerbation after bariatric surgery in adults

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives Iris M. Otani, MD, Sandra C. Christiansen, MD, Paula Busse, MD,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

The Natural History of Food Allergy

Luciana Kase Tanno, MD, PhD, Moises A

Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed Leonard Bielory, MD The Journal of Allergy and Clinical Immunology:

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Desensitization to Chemotherapeutic Agents

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Adult Asthma Scores—Development and Validation of Multivariable Scores to Identify Asthma in Surveys Ana Sá-Sousa, MSc, Ana Margarida Pereira, MD, Rute.

Robert G. Hamilton, PhD, John Oppenheimer, MD

Michael Schatz, MD, MS, Robert S

Comparative Effectiveness of Budesonide-Formoterol Combination and Fluticasone- Salmeterol Combination for Asthma Management: A United States Retrospective.

Robert S. Zeiger, MD, PhD, Michael Schatz, MD, MS, Anand A

Impact of Asthma Exacerbations and Asthma Triggers on Asthma-related Quality of Life in Patients with Severe or Difficult-to-Treat Asthma Allan T. Luskin,

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Test for Respiratory and Asthma Control in Kids (TRACK): A caregiver-completed questionnaire for preschool-aged children Kevin R. Murphy, MD, Robert.

Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review Amy S. Levin, MD, Iris M. Otani, MD, Timothy Lax, MD, Ephraim Hochberg, MD, Aleena.

Validation of the Pregnancy Asthma Control Test

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Advances in Diagnosing Peanut Allergy

Nonadherence to Asthma Treatment: Getting Unstuck

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Smoking Cessation as a Possible Risk Factor for the Development of Aspirin- Exacerbated Respiratory Disease in Smokers Hiroaki Hayashi, MD, Yuma Fukutomi,

Thys van der Molen, MD, PhD, Monica Fletcher, MSc, David Price, FRCGP

Consistently very poorly controlled asthma is associated with greater activity and school impairment in children with severe or difficult-to-treat asthma

The HEDIS Medication Management for People with Asthma Measure is Not Related to Improved Asthma Outcomes Angelina Crans Yoon, MD, William Crawford,

Value of a Second Dose of Epinephrine During Anaphylaxis: A Patient/Caregiver Survey T. Ted Song, DO, Duncan Brown, PhD, Martin Karjalainen, MD, Ulrike.

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Necdet B. Gunsoy, PhD, Sarah M. Cockle, PhD, Steven W

Penicillin Skin Testing Is a Safe and Effective Tool for Evaluating Penicillin Allergy in the Pediatric Population Stephanie J. Fox, MD, Miguel A. Park,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

Change in Asthma Control Over Time: Predictors and Outcomes

Phillip Lieberman, MD, Michael Tankersley, MD

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Trends in Hospitalizations and Mortality From Asthma in Costa Rica Over a 12- to 15- year Period Manuel Soto-Martínez, MD, Lydiana Avila, MD, Natalia.

Pinja Ilmarinen, PhD, Leena E

Effects of Mometasone, Fluticasone, and Montelukast on Bone Mineral Density in Adults with Asthma Jorge Maspero, MD, Vibeke Backer, DMSci, MD, Ruji Yao,

Thomas B. Casale, MD, Tmirah Haselkorn, PhD, Christina E

Phillip Lieberman, MD, David Golden, MD

Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study Bradley E.

Russell S. Traister, MD, PhD, Merritt L

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Michael Schatz, MD, MS, Robert S

Mapping the Asthma Care Process: Implications for Research and Practice Alexandra Lelia Dima, PhD, Marijn de Bruin, PhD, Eric Van Ganse, MD, PhD, FRCP

Pinja Ilmarinen, PhD, Leena E

Real-world attitudes among allergists/immunologists regarding oral immunotherapy and preferred terminology Bradley E. Chipps, MD, Christina E. Ciaccio,

Sharon Seth, MD, David A. Khan, MD

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Cephalosporin Side Chain Cross-reactivity

Robert S. Zeiger, MD, PhD, Michael Schatz, MD, MS, Anand A

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Addition of mycophenolate mofetil to tacrolimus is associated with decreases in food- specific IgE levels in a pediatric patient with liver transplantation-associated.

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe.

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

News & Notes Journal of Allergy and Clinical Immunology

Presentation transcript:

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan T. Luskin, MD, William Busse, MD, Robert S. Zeiger, MD, PhD, Benjamin Trzaskoma, MS, Ming Yang, PhD, Noelle M. Griffin, PhD, Bradley E. Chipps, MD The Journal of Allergy and Clinical Immunology: In Practice Volume 7, Issue 1, Pages 156-164.e1 (January 2019) DOI: 10.1016/j.jaip.2018.04.043 Copyright © 2019 The Authors Terms and Conditions

Figure 1 Patient disposition. Noncompliance was defined as an indication that a patient has not agreed with or followed the instructions related to the protocol. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 156-164.e1DOI: (10.1016/j.jaip.2018.04.043) Copyright © 2019 The Authors Terms and Conditions

Figure 2 Mean exacerbation rate by (A) age group and (B) biomarker status. *P < .0001 for comparison of before study entry to through 12 months on study for each age group (calculation based on simulation). Sum of exacerbations is not adjusted to patient's time on study. †Baseline: mean ± SD; through month 12: least squares (mean). ‡P values reflect adjustments for differences in baseline characteristics. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 156-164.e1DOI: (10.1016/j.jaip.2018.04.043) Copyright © 2019 The Authors Terms and Conditions

Figure 3 Percentage of patients with 1 or more hospitalizations by (A) age group and (B) biomarker status. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 156-164.e1DOI: (10.1016/j.jaip.2018.04.043) Copyright © 2019 The Authors Terms and Conditions

Figure 4 Mean prebronchodilator FEV1 (L) by age group (for patients with spirometry at baseline and end of the study). The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 156-164.e1DOI: (10.1016/j.jaip.2018.04.043) Copyright © 2019 The Authors Terms and Conditions

Figure 5 Mean ACT score 12 months after omalizumab initiation by (A) age group and (B) asthma severity. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 156-164.e1DOI: (10.1016/j.jaip.2018.04.043) Copyright © 2019 The Authors Terms and Conditions

Figure 6 Impact of biomarker status on ACT outcomes. (A) Mean change from baseline in ACT score 12 months after omalizumab initiation in adults. (B) Percentage of patients with well-controlled asthma. P values reflect adjustment for difference in baseline characteristics. *Baseline mean ± SD; through month 12 least squares mean (SE). The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 156-164.e1DOI: (10.1016/j.jaip.2018.04.043) Copyright © 2019 The Authors Terms and Conditions

Figure E1 Exacerbation rate before study entry and through 12 months on study for patients with IgE levels outside the limits of the omalizumab dosing table. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, 156-164.e1DOI: (10.1016/j.jaip.2018.04.043) Copyright © 2019 The Authors Terms and Conditions